SCHEMBL5192164

SCHEMBL5192164

CC1C(=O)N(C)C(=O)N1c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.41
LOX P28300 1/20 0.40
LOXL3 P58215 1/20 0.40
LOXL4 Q96JB6 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
TSHR P16473 1/20 0.37
GAA P10253 1/20 0.37
G6PD P11413 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713101 0.83 MAOA (0.48) MAOALOXLOXL3LOXL4LOXL2
SCHEMBL23941231 0.81 GSK3A (0.37) MAOALOXLOXL3LOXL4LOXL2
SCHEMBL9835334 0.81 MAOA (0.47) MAOALOXLOXL3LOXL4LOXL2
SCHEMBL19923522 0.81 SMO (0.53) MAOAKMT2AMEN1GAACACNA1B
SCHEMBL19923639 0.77 MAOA (0.41) MAOALOXLOXL3LOXL4LOXL2
SCHEMBL28410578 0.77 MAOA (0.38) MAOALOXLOXL3LOXL4LOXL2
SCHEMBL18937410 0.77 MAOA (0.38) MAOALOXLOXL3LOXL4LOXL2
SCHEMBL19923535 0.76 CYP1A2 (0.40) MAOALOXLOXL3LOXL4LOXL2
SCHEMBL19923679 0.75 LOX (0.39) MAOALOXLOXL3LOXL4LOXL2
SCHEMBL10909817 0.75 MAOA (0.37) MAOALOXLOXL3LOXL4LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1144366-B1 3,4-DISUBSTITUTED ACYLANILIDE DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA INC (US) 2007-06-27 EP disclosed
US-6861432-B2 Piperazine derivatives that destabilize androgen receptors SCHERING AKTIENGESELLSCHAFT (DE) 2005-03-01 US disclosed
US-6828458-B2 Topical antiandrogen for hair loss and other hyperandrogenic conditions BIOPHYSICA, INC. 2004-12-07 US disclosed
EP-1169301-B1 A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS BIOPHYSICA INC (US) 2004-02-18 EP disclosed
US-20040014732-A1 A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS BIOPHYSICA, INC. (US) 2004-01-22 US disclosed
US-20040009969-A1 Piperazine derivatives that destabilize androgen receptors SCHERING AG (DE) 2004-01-15 US disclosed
EP-1144366-A3 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA, INC. (US) 2003-06-04 EP disclosed
WO-2001058855-A9 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA INC (US) 2002-10-31 WO disclosed
US-6472415-B1 Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes BIOPHYSICA, INC. 2002-10-29 US disclosed
EP-1169301-A1 A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS BIOPHYSICA, INC. (US) 2002-01-09 EP disclosed
EP-1144366-A2 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA, INC. (US) 2001-10-17 EP disclosed
WO-2001058855-A1 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA, INC (US) 2001-08-16 WO disclosed
WO-2001058854-A1 A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS BIOPHYSICA, INC. (US) 2001-08-16 WO disclosed
US-6184249-B1 Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes BIOPHYSICA, INC. 2001-02-06 US disclosed
WO-2000037430-A2 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA, INC. (US) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014732-A1 A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS AR, NR5A1, FSHR MAOA 1938/4885LOX 3634/4885LOXL3 2268/4885
US-20040009969-A1 Piperazine derivatives that destabilize androgen receptors AR, FSHR, GNRHR MAOA 3564/4885LOX 4276/4885LOXL3 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.